IRX4204 Induces Senescence and Cell Death in HER2-Positive Breast Cancer and Synergizes with Anti-HER2 Therapy

Scientists examined the efficacy of IRX4204, a highly specific rexinoid, in breast cancer cell lines and preclinical models to identify a biomarker for response and potential mechanism of action.